The FDA said in a statement that it had determined that one of the two approved vaccines, Ixchiq (Valneva SE), which contains a live, weakened version of the chikungunya virus, was responsible for 21 ...

In a report released today, from Stifel Nicolaus maintained a Buy rating on Valneva, with a price target of €9.50. The company’s shares opened today at €3.78. Elevate Your I ...

The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.

In a U-turn from a decision two weeks ago, the FDA – citing new safety events – said the vaccine is a "danger to health".